麻豆传媒

The a new guideline for the pharmacological treatment of type 2 diabetes in adults, strongly recommending the addition of an SGLT2 inhibitor or GLP-1 receptor agonist, but not a DPP-4 inhibitor to metformin and lifestyle interventions to reduce all-cause mortality risk for those with inadequate glucose control. (Annals of Internal Medicine)

In related news, the American Diabetes Association released its for primary care professionals. (Clinical Diabetes)

People with -- a selective cortisol modulator -- had rapid and sustained improvements in both systolic and diastolic blood pressure over 22 weeks, said Corcept Therapeutics. Responders who entered a withdrawal phase continued to have blood pressure improvements in the two-part phase III GRACE trial.

Senators are on why a popular long-acting insulin (Levemir) is being discontinued. (USA Today)

Almost all doses of the (Mounjaro, Zepbound) for type 2 diabetes and obesity will be in short supply through the second quarter of this year, the FDA website showed. (Reuters)

And how should the be allocated? Experts weighed in. (New England Journal of Medicine)

Meanwhile, the continued shortage of the since fall 2022 is still affecting patients with hormone deficiencies like Prader-Willi syndrome. (NPR)

Under a new rule from the Environmental Protection Agency, to clean up perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) -- two so-called forever chemicals linked to serious health risks -- shifting responsibility from taxpayers. (New York Times)

"All of a sudden they'd quit smoking," said family nurse practitioner Luba Yammine, PhD, MSN, about to treat patients with type 2 diabetes, in a JAMA perspective.

People with type 1 diabetes significantly reduced their average total daily dose of insulin over 12 weeks. On the other hand, those on a portion-controlled diet had no change in insulin needs. (Clinical Diabetes)

Racial discrimination in adolescence may in adulthood, a longitudinal cohort study suggested. (JAMA Network Open)

Can the diabetes mainstay ? Researchers are looking to find out. (NPR)

Real-world data showed a significantly lower incidence of with abaloparatide (Tymlos) among women ages 50 and older with osteoporosis compared with teriparatide (Forteo), said Radius Pharmaceuticals.

Correction: A previous version of this roundup incorrectly stated that the American College of Physicians' guidelines recommended adding a DPP-4 inhibitor to metformin and lifestyle interventions to reduce all-cause mortality risk for those with type 2 diabetes and inadequate glucose control.

Comment